HomeCompareKRA vs ABBV

KRA vs ABBV: Dividend Comparison 2026

KRA yields 4.30% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.8K in total portfolio value
10 years
KRA
KRA
● Live price
4.30%
Share price
$46.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$566.87
Full KRA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KRA vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KRA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRA
Annual income on $10K today (after 15% tax)
$365.67/yr
After 10yr DRIP, annual income (after tax)
$481.84/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,574.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRA + ABBV for your $10,000?

KRA: 50%ABBV: 50%
100% ABBV50/50100% KRA
Portfolio after 10yr
$64.4K
Annual income
$12,669.32/yr
Blended yield
19.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KRA
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRA buys
0
ABBV buys
0
No recent congressional trades found for KRA or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRAABBV
Forward yield4.30%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$26.5K$102.3K
Annual income after 10y$566.87$24,771.77
Total dividends collected$5.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KRA vs ABBV ($10,000, DRIP)

YearKRA PortfolioKRA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,130$430.20$11,550$430.00$420.00ABBV
2$12,357$447.50$13,472$627.96$1.1KABBV
3$13,686$464.31$15,906$926.08$2.2KABBV
4$15,125$480.62$19,071$1,382.55$3.9KABBV
5$16,680$496.39$23,302$2,095.81$6.6KABBV
6$18,359$511.62$29,150$3,237.93$10.8KABBV
7$20,170$526.28$37,536$5,121.41$17.4KABBV
8$22,123$540.38$50,079$8,338.38$28.0KABBV
9$24,225$553.91$69,753$14,065.80$45.5KABBV
10$26,488$566.87$102,337$24,771.77$75.8KABBV

KRA vs ABBV: Complete Analysis 2026

KRAStock

Kraton Corporation manufactures and sells styrenic block copolymers, specialty polymers, and bio-based products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Polymer and Chemical. The Polymer segment offers performance products, including styrene-butadiene-styrene for paving and roofing application; styrene-isoprene-styrene for personal care application; ethylene-vinyl acetate, polyolefins, and metallocene polyolefins for adhesives application; and specialty polymers, such as hydrogenated styrenic block copolymer, isoprene rubber, and isoprene rubber latex for use in medical and personal care products, adhesives, tackifiers, paints, and coatings. The Chemical segment provides pine-based specialty products that include rosin-based tackifiers for packaging and pressure-sensitive adhesive applications; terpene-based tackifiers for bookbinding, hygiene, and pressure-sensitive adhesive applications; alpha-methyl-styrene (AMS) resins; and hot melt polyamides for flexible packaging, industrial and road making applications. This segment also provides tall oil fatty acids, tall oil rosin, distilled tall oil, tall oil pitch, and rosin-based binders for the thermoplastic pavement marking submarket, as well as produces insoluble maleic-based tackifiers. The Chemical segment also offers terpene-based tread enhancement resins and AMS-based tread enhancement additives; and dimer acids and terpene fractions for fuel additives, oilfield chemicals, mining fluids, coatings, metalworking fluids, and lubricants. The company sells its products through various channels, including direct sales force, marketing representatives, and distributors under the Kraton brand. The company was formerly known as Kraton Performance Polymers, Inc. and changed its name to Kraton Corporation in September 2016. Kraton Corporation was incorporated in 2009 and is based in Houston, Texas.

Full KRA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KRA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRA vs SCHDKRA vs JEPIKRA vs OKRA vs KOKRA vs MAINKRA vs JNJKRA vs MRKKRA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.